The First-in-human Study of SRN-001 in Healthy Participants
A Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of SRN-001 in Healthy Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Dongho Kim
- Phone Number: +82-42-930-8654
- Email: dongho-kim@sirnagen.com
Study Locations
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- CMAX Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-70
- BMI ≥18.0 kg/㎡ and ≤35 kg/㎡
- 12-lead triplicate electrocardiogram (ECG) readings within normal limits or with no clinically significant abnormalities
- systolic blood pressure ≥ 90 mmHg and ≤160 mmHg; a diastolic blood pressure ≥ 50 mmHg and ≤95 mmHg; pulse ≥ 45 bpm and ≤100 bpm; tympanic temperature ≥ 35.5°C and ≤37.7°C and respiratory rate 12rpm to 22rpm
- Negative urinary cotinine
- Compliance to contraception and sperm donation restriction
- Participants who are able and willing to give written informed consent
- Fully vaccinated against SARS-CoV-2
Exclusion Criteria:
- Who has clinically significant history
- Who is with history of multiple drug allergies or history of allergic reaction to an oligonucleotide or common medicine (eg, aspirin, antibiotics, etc) or clinically significant hypersensitivity
- No tolerance to IV injections or significant potential of intolerance
- Clinically significant surgical history within 1 year
- History of drug abuse or alcoholism within 2 years, and a restriction of consuming alcohol during study period
- Pregnant or lactating females
- Liver function test is 1.5 times greater than upper limit of normal (ULN)
- Albumin ≥ 35 g/L and ≤ 50 g/L
- Hb < 115 g/L (female), < 125 g/L (male)
- estimated glomerular filtration rate (eGFR) < 60 mL/min (CKD-EPI), 90 mL/min (MDRD)
- Glucose < 3 mmol/L
- Positive screen for alcohol or drugs of abuse
- HBsAg, Hepatitis B virus (HBV), Hepatitis C virus (HCV), or HIV infection
- QTcF > 450 msec for male, > 470 msec for female
- Inappropriate lab result by physician's discretion
- Who have donated > 500 mL of blood within 3 months
- Who have received an investigational agent within 3 months, or 5 half-lives
- Who have used prescription medication within 4 weeks including vaccines
- Who have used OTC medication within 7 days
- With clinically relevant wounds, following a clinically relevant surgery or have recently completed any invasive procedures (ie, Endoscopy) within 1 week, or who are scheduled for an elective surgical procedure
- Who have a significant infection or known inflammatory process ongoing
- Any conditions that, in physician's opinion, would make the participant unsuitable for enrollment or could interfere with the participant's participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
0.9% Sodium Chloride(Normal saline)
|
|
Experimental: SRN-001
|
siRNA therapeutics, Self Assembled Micelle inhibitory RNA platform utilized
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants with treatment-emergent adverse events(TEAEs)
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
|
Number of participants with serious adverse events(SAEs)
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cmax
Time Frame: Up to 168 hours post-dose
|
Maximum observed concentration
|
Up to 168 hours post-dose
|
|
Clast
Time Frame: Up to 168 hours post-dose
|
Observed concentration corresponding to Tlast
|
Up to 168 hours post-dose
|
|
Tlast
Time Frame: Up to 168 hours post-dose
|
Time of last measurable observed concentration
|
Up to 168 hours post-dose
|
|
AUClast
Time Frame: Up to 168 hours post-dose
|
Area under the drug concentration-time curve, from time zero to the last measurable concentration
|
Up to 168 hours post-dose
|
|
AUCinf
Time Frame: Up to 168 hours post-dose
|
Area under the drug concentration-time curve, from time zero to infinity
|
Up to 168 hours post-dose
|
|
T½
Time Frame: Up to 168 hours post-dose
|
Apparent terminal half-life
|
Up to 168 hours post-dose
|
|
Kel
Time Frame: Up to 168 hours post-dose
|
Apparent terminal elimination rate constant
|
Up to 168 hours post-dose
|
|
CL
Time Frame: Up to 168 hours post-dose
|
Total body clearance
|
Up to 168 hours post-dose
|
|
Vz
Time Frame: Up to 168 hours post-dose
|
Volume of distribution
|
Up to 168 hours post-dose
|
|
MRT
Time Frame: Up to 168 hours post-dose
|
Mean residence time
|
Up to 168 hours post-dose
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of treatment-emergent Anti-Drug Antibody(ADA)
Time Frame: Up to 672 hours post-dose
|
Up to 672 hours post-dose
|
|
Change from baseline in specific biomarkers
Time Frame: Up to 24 hours post-dose
|
Up to 24 hours post-dose
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SRN-001-C01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.